StockData

Orchestra BioMed vs Stereotaxis

OBIO and STXS side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How OBIO and STXS compare

Orchestra BioMed is the larger company, worth 4.7 times as much as Stereotaxis ($419M against $88.4M).

Orchestra BioMed grew revenue faster over the last twelve months (986% versus −5.5% for Stereotaxis).

Stereotaxis keeps more of each dollar of sales as profit, with a net margin of −74.2% compared with −185% at Orchestra BioMed.

Orchestra BioMed scores higher on the StockData Score (9 against 7 for Stereotaxis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricOBIOSTXS
Size and price
Market cap$419M$88.4M
Share price$6.97$0.882
Change, 1 year76.9%−60.3%
Change, 5 years−29.3%−85.2%
Beta (5Y)1.151.00
Employees86131
StockData Score
Total score9 (better)7
Valuation score01 (better)
Growth score3 (better)1
Performance score1 (better)0
Health score55
Dividend score00
Valuation
P/S13.1×2.9× (better)
P/B–7.2×
FCF yield−14.1% (better)−17.5%
Fair value–$1.08
Margin of safety–18.0%
Growth
Revenue growth (TTM)986% (better)−5.5%
Revenue growth, 5Y average–4.0%
Profitability
Gross margin99.5% (better)55.6%
Operating margin−181%−75.7% (better)
Net margin−185%−74.2% (better)
FCF margin−185%−51.6% (better)
Return on equity–−326%
Financial health
Debt / equity–0.00
Current ratio8.26 (better)1.42
Altman Z-score−2.38 (better)−14.13
Piotroski F-score6 (better)5
Dividends and buybacks
Buyback yield–−24.0%
Shareholder yield0.00% (better)−24.0%
Ownership
Held by institutions46.1%43.0%
Held by insiders56.6%20.3%
Insider net buying, 12 months$6.1M (better)$0
Short interest, % of float10.5%7.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.